EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 39 / No 11 (Novembre 2023) Med Sci (Paris), 39 11 (2023) 855-861 References
Open Access
Issue
Med Sci (Paris)
Volume 39, Number 11, Novembre 2023
Page(s) 855 - 861
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2023162
Published online 29 November 2023
  1. Sironi M, Forni D, de la Torre J.-C. Mammarenavirus Genetic Diversity and Its Biological Implications. Cur Top Microbiol Immunol 2023; 439 : 265–303. [Google Scholar]
  2. Buchmeier MJ, de la Torre JC, and Peters CJ. Arenaviridae. Fields virology. Philadelphia, Pennsylvania, USA. : Lippincott Williams & Wilkins, Wolters Kluwer 2013 : pp. 1283–303. [Google Scholar]
  3. Briese T, Paweska JT, McMullan LK, et al. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog 2009 ; 5 : e1000455. [CrossRef] [PubMed] [Google Scholar]
  4. Monath TP, Newhouse VF, Kemp GE, et al. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 1974 ; 185 : 263–265. [CrossRef] [PubMed] [Google Scholar]
  5. Olayemi A, Cadar D, Magassouba N, et al. New Hosts of The Lassa Virus. Sci Rep 2016 ; 6 : 25280. [CrossRef] [PubMed] [Google Scholar]
  6. McCormick JB, Fisher-Hoch SPLassa fever. Cur Top. Microbiol Immunol 2002 ; 262 : 75–109. [Google Scholar]
  7. Merson L, Bourner J, Jalloh S, et al. Clinical characterization of Lassa fever : A systematic review of clinical reports and research to inform clinical trial design. PLoS Negl Trop Dis 2021; 15 : e0009788. [CrossRef] [PubMed] [Google Scholar]
  8. Robinson JE, Hastie KM, Cross RW, et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun 2016 ; 7 : 11544. [CrossRef] [PubMed] [Google Scholar]
  9. Ugwu C, Olumade T, Nwakpakpa E, et al. Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria. Sci Rep 2022; 12 : 22330. [CrossRef] [PubMed] [Google Scholar]
  10. Garry RF. Lassa fever - the road ahead. Nat Rev Microbiol 2023; 21 : 87–96. [CrossRef] [PubMed] [Google Scholar]
  11. Eberhardt KA, Mischlinger J, Jordan S, et al. Ribavirin for the treatment of Lassa fever : A systematic review and meta-analysis. Int J Infect Dis 2019 ; 87 : 15–20. [CrossRef] [PubMed] [Google Scholar]
  12. Salam apr., Cheng V, Edwards T, et al. Time to reconsider the role of ribavirin in Lassa fever. PLoS Negl Trop Dis 2021; 15 : e0009522. [CrossRef] [PubMed] [Google Scholar]
  13. Ambrosio A, Saavedra M, Mariani M, et al. Argentine hemorrhagic fever vaccines. Hum Vaccin 2011 ; 7 : 694–700. [CrossRef] [PubMed] [Google Scholar]
  14. Silva-Ramos CR, Faccini-Martinez AA, Calixto OJ, Hidalgo M. Bolivian hemorrhagic fever : A narrative review. Travel Med Infect Dis 2021; 40 : 102001. [CrossRef] [PubMed] [Google Scholar]
  15. Patterson M, Grant A, Paessler S Epidemiology and pathogenesis of Bolivian hemorrhagic fever. Curr Opin Virol 2014 ; 5 : 82–90. [CrossRef] [PubMed] [Google Scholar]
  16. Silva-Ramos CR, Montoya-Ruiz C, Faccini-Martinez AA, Rodas J.-D. An updated review and current challenges of Guanarito virus infection, Venezuelan hemorrhagic fever. Arch Virol 2022; 167 : 1727–38. [CrossRef] [PubMed] [Google Scholar]
  17. Nastri AC, Duarte-Neto AN, Casadio LVB, et al. Understanding Sabia virus infections (Brazilian mammarenavirus). Travel Med Infect Dis 2022; 48 : 102351. [CrossRef] [PubMed] [Google Scholar]
  18. Loayza Mafayle R, Morales-Betoulle ME, Romero C, et al. Chapare Hemorrhagic Fever and Virus Detection in Rodents in Bolivia in 2019. N Engl J Med 2022; 386 : 2283–94. [CrossRef] [PubMed] [Google Scholar]
  19. Frank MG, Beitscher A, Webb CM, et al. South American Hemorrhagic Fevers : A summary for clinicians. Int J Infect Dis 2021; 105 : 505–15. [CrossRef] [PubMed] [Google Scholar]
  20. Levis SC, Saavedra MC, Ceccoli C, et al. Endogenous interferon in Argentine hemorrhagic fever. J Infect Dis 1984 ; 149 : 428–433. [CrossRef] [PubMed] [Google Scholar]
  21. Levis SC, Saavedra MC, Ceccoli C, et al. Correlation between endogenous interferon and the clinical evolution of patients with Argentine hemorrhagic fever. J Interferon Res 1985 ; 5 : 383–389. [CrossRef] [PubMed] [Google Scholar]
  22. Maiztegui JI, Fernandez NJ, de Damilano AJEfficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979 ; 2 : 1216–1217. [CrossRef] [Google Scholar]
  23. Salami K, Gouglas D, Schmaljohn C, et al. A review of Lassa fever vaccine candidates. Curr Opin Virology 2019 ; 37 : 105–111. [CrossRef] [Google Scholar]
  24. Tang-Huau TL, Feldmann H, Rosenke KAnimal models for Lassa virus infection. Curr Opin Virol 2019 ; 37 : 112–117. [CrossRef] [PubMed] [Google Scholar]
  25. WHO Target Product Profile for Lassa virus Vaccine. https://www.who.int/publications/m/item/who-target-product-profile-for-lassa-virus-vaccine. [Google Scholar]
  26. Yadouleton A, Picard C, Rieger T, et al. Lassa fever in Benin : description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus. Emerg Microbes Infect 2020; 9 : 1761–70. [CrossRef] [PubMed] [Google Scholar]
  27. Kafetzopoulou LE, Pullan ST, Lemey P, et al. Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. Science 2019 ; 363 : 74–77. [Google Scholar]
  28. Cashman KA, Wilkinson ER, Shaia CI, et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum Vacc Immunother 2017 ; 13 : 2902–2911. [CrossRef] [PubMed] [Google Scholar]
  29. Jiang J, Banglore P, Cashman KA, et al. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques. Hum Vacc Immunother 2019 : 1–9. [Google Scholar]
  30. Ollmann Saphire E. A Vaccine against Ebola Virus. Cell 2020; 181 : 6. [CrossRef] [PubMed] [Google Scholar]
  31. Geisbert TW, Jones S, Fritz EA, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005 ; 2 : e183. [CrossRef] [PubMed] [Google Scholar]
  32. Cross RW, Woolsey C, Prasad AN, et al. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever. Cell Rep 2022; 40 : 111094. [CrossRef] [PubMed] [Google Scholar]
  33. Safronetz D, Mire C, Rosenke K, et al. A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses. PLoS Negl Trop Dis 2015 ; 9 : e0003736. [CrossRef] [PubMed] [Google Scholar]
  34. Lukashevich IS, Patterson J, Carrion R, et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 2005 ; 79 : 13934–13942. [CrossRef] [PubMed] [Google Scholar]
  35. Kiley MP, Lange JV, Johnson KMProtection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet 1979 ; 2 : 738. [CrossRef] [Google Scholar]
  36. Lukashevich IS, Carrion R, Jr, Salvato MS, et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 2008 ; 26 : 5246–5254. [CrossRef] [PubMed] [Google Scholar]
  37. Carnec X, Mateo M, Page A, et al. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins. J Virol 2018 ; 92 : [CrossRef] [PubMed] [Google Scholar]
  38. Carnec X, Baize S, Reynard S, et al. Lassa virus nucleoprotein mutants generated by reverse genetics induce robust type I IFN response in human dendritic cells and macrophages. J Virol 2011 ; 85 : 12093–12097. [CrossRef] [PubMed] [Google Scholar]
  39. Mateo M, Reynard S, Carnec X, et al. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Sci Transl Med 2019; 11 : eaaw3163. [PubMed] [Google Scholar]
  40. Baize S. Une vaccination efficace en dose unique contre la fièvre de Lassa. Med Sci (Paris) 2020; 36 : 844–7. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  41. Mateo M, Reynard S, Journeaux A, et al. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Sci Transl Med 2021; 13 : eabf6348. [CrossRef] [PubMed] [Google Scholar]
  42. Mateo M, Reynard S, Pietrosemoli N, et al. Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys. Nat Commun 2023; 14 : 1352. [CrossRef] [PubMed] [Google Scholar]
  43. Tschismarov R, Van Damme P, Germain C, et al. Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine : a randomised, placebo-controlled, first-in-human trial. Lancet 2023; 401 : 1267–76. [CrossRef] [PubMed] [Google Scholar]
  44. Samoilovich SR Pecci Saavedra J, Frigerio MJ, Weissenbacher MC. Nasal and intrathalamic inoculations of primates with Tacaribe virus : protection against Argentine hemorrhagic fever and absence of neurovirulence. Acta Virol 1984 ; 28 : 277–281. [PubMed] [Google Scholar]
  45. McKee KT J.-R., Oro JG, Kuehne AI, et al. Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. Intervirology 1992 ; 34 : 154–163. [CrossRef] [PubMed] [Google Scholar]
  46. Maiztegui JI, McKee KT J.-R., Barrera Oro JG, et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis 1998 ; 177 : 277–283. [CrossRef] [PubMed] [Google Scholar]
  47. Reynard S, Carnec X, Picard C, et al. A MOPEVAC multivalent vaccine induces sterile protection against New World arenaviruses in non-human primates. Nat Microbiol 2023; 8 : 64–76. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.